Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2024-07-05 Earnings Release
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
Earnings Release Classification · 99% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and dated July 5, 2024. It provides an update on clinical trial progress (NATiV3), patent protection, and the company's financial position, including an estimate of its cash runway and the need to secure financing. This format—a brief, high-level summary of recent operational and financial developments released to the public and media—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on operational updates and financial position rather than just the detailed financial results themselves (which would be an IR or MDA), and it is a press release format, it aligns best with the Earnings Release (ER) definition, which covers initial announcements of periodical results and key highlights. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or a transcript (CT). Given the focus on financial position and operational milestones announced via press release, ER is the most appropriate classification. FY 2024
2024-07-05 English
DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS AUTORISE PAR L'ASSEMBLEE GENERALE ORDINAIRE DU 20 JUIN 2024
Transaction in Own Shares Classification · 100% confidence The document is titled "DESCRIPTIF DU PROGRAMME DE RACHAT D'ACTIONS AUTORISE PAR L'ASSEMBLEE GENERALE ORDINAIRE DU 20 JUIN 2024" (Description of the Share Buyback Program Authorized by the Ordinary General Meeting of June 20, 2024). It details the objectives, maximum price, duration, and mechanics of a share repurchase program authorized by a shareholder meeting. This content directly relates to the company's capital structure management and transactions involving its own shares. The most specific category for reporting the company buying back its own shares is 'Transaction in Own Shares' (POS). While it mentions the AGM authorization, the core subject is the buyback plan itself, not the AGM materials (AGM-R) or a general capital change (CAP).
2024-06-21 French
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024
AGM Information Classification · 99% confidence The document is titled "DESCRIPTION OF THE SHARE REPURCHASE PROGRAM AUTHORISED BY THE ORDINARY GENERAL MEETING OF 20 JUNE 2024" and details the objectives, maximum proportion of capital, maximum number of shares, maximum price, and duration of a share repurchase program. This directly relates to the company buying back or selling its own shares, which corresponds to the 'Transaction in Own Shares' category (POS). Although it mentions the AGM authorization, the core content is the description of the repurchase plan itself, not the AGM materials (AGM-R) or a general announcement of a report (RPA/RNS). The length (13013 chars) suggests it is the substantive document, not just a brief announcement.
2024-06-21 English
Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunies le 20 juin 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document title explicitly states: "Résultats des votes de l'Assemblée Générale Mixte des actionnaires réunies le 20 juin 2024" (Results of the votes of the Combined General Meeting of shareholders held on June 20, 2024). The content details the adoption and rejection of various resolutions voted upon during this meeting, including specific vote counts. This directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). It is not an AGM presentation (AGM-R), nor is it a proxy solicitation document (PSI), but the official results announcement.
2024-06-21 French
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
AGM Information Classification · 99% confidence The document is explicitly titled "Results of the votes of the Combined Shareholders' General Meeting of June 20, 2024". It details the adoption and rejection status of various resolutions voted upon during this meeting, including specific vote counts and quorum information. This content directly corresponds to the official results of a shareholder vote, which aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it mentions compensation policy (related to DEF 14A), the primary focus and structure are the vote outcomes.
2024-06-21 English
Information relative au nombre total de droits de vote et d’actions composant le capital social au 13 mai 2024
Share Issue/Capital Change Classification · 95% confidence The document is a formal press release from Inventiva titled 'Information relative au nombre total de droits de vote et d'actions composant le capital social'. This is a standard regulatory disclosure required under French law (Article R. 22-10-23 of the Commercial Code) to inform the public about the number of shares and voting rights. Since it does not fit into specific categories like 'Share Issue' (which would imply a new issuance event) or 'Major Shareholding' (which would be a notification from a shareholder), it falls under the general regulatory announcement category.
2024-05-30 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.